Tempus AI has announced that it is using the TIME Network to support Phase I trials and expedite site activation and enrolment.

The company has created the TIME Precision Network, a team of investigators that will lead the Phase I trial platform, concentrating on fast activation and enrolment at more than 40 research centres equipped for these trials.

The network recently enrolled the first patient in several Phase I trials.

Established in 2019, TIME is said to have been instrumental in identifying subjects and activating sites for trials, making them accessible to patients in various communities throughout the US.

Tempus noted that the network is designed for efficient subject enrolment, leveraging a base of data-integrated sites where subjects are matched with appropriate trials, and sites can be activated in a matter of days or weeks.

The company said that it conducted site activation at the Taylor Cancer Research Centre in the US in nearly two weeks for the Nimbus 9216-101 trial and conducted the first subject enrolment within a 30-day period of activation.

For the Pathos P300-02-001 trial, the company similarly carried out screening and enrolment procedures for the trial’s first and second subjects at Nebraska Cancer Specialists and Oncology Consultants within a short time frame.

Tempus has developed a network that includes several community hospitals, which are crucial for serving under-represented subject groups.

This initiative aims to widen the availability of trials, thereby diminishing barriers to participation and providing subjects with access to investigational therapies.

Tempus Oncology chief medical officer Ezra Cohen said: “The integration of Phase I clinical trial sites adds a critical capability to the TIME Network. We are now able to activate and efficiently execute these early studies that are fundamental to drug development and such a valuable offering to patients.

“The reality is that these studies require specific and coordinated infrastructure to be successful, and I am proud that Tempus can now work with these sites and our life science partners to enrol patients into these cutting-edge clinical trials.”